Company: ABUS
Filing Date: 2025-06-25
Form Type: 8-K
Source: 0001171843-25-004094
Chunk: 1

Company: Arbutus Biopharma Corp
Filing Date: 2025-06-25
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01. Other Events.

On June 25, 2025, Arbutus issued a press release announcing the reacquisition of imdusiran rights in Greater China and Taiwan, the termination of the License Agreement with Qilu, and its new Scientific Advisory Board. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit Number      Description                                                                                                                 
  10.1 †              Termination Agreement, dated June 20, 2025, by and between Arbutus Biopharma Corporation and Qilu Pharmaceutical Co., Ltd.  
  99.1                Press Release dated June 25, 2025                                                                                           
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  104                 Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                 

† Certain confidential portions of the agreement were omitted by means of marking such portions with brackets (due to the registrant customarily and actually treating such information as private or confidential and such omitted information not being material) pursuant to Item 601 of Regulation S-K promulgated by the SEC. Arbutus agrees to supplementally furnish a copy of any confidential portions to the SEC upon request.